Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Peptide drug conjugates | 2 |
Fluorescent Peptide | 1 |
Diagnostic radiopharmaceuticals | 1 |
Top 5 Target | Count |
---|---|
TfR1(Transferrin receptor protein 1) | 1 |
chloride channel(Chloride channels) | 1 |
Target |
Mechanism chloride channel modulators |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TfR1 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date17 Apr 2024 |
Sponsor / Collaborator |
Start Date30 Sep 2021 |
Sponsor / Collaborator |
Start Date26 Nov 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
TfR1(Blaze) ( TfR1 ) | Central Nervous System Diseases More | Preclinical |
CDP-11R-TAA | Arthritis More | Preclinical |
Tozuleristide ( chloride channel ) | Glioma More | Pending |